Dr Reddys Q4 net loss at Rs 14.01 cr | Latest News India - Hindustan Times
close_game
close_game

Dr Reddys Q4 net loss at Rs 14.01 cr

None | ByPress Trust of India, Mumbai
May 31, 2006 05:24 PM IST

Dr Reddys posted a net loss of Rs 14.01 crore for the quarter ended March 31.

Dr Reddys Laboratories Ltd on Wednesday posted a net loss of Rs 14.01 crore for the quarter ended March 31 as compared to a net loss of Rs 8.75 crore for the same quarter in 2004-05.

HT Image
HT Image

Total income (net of excise), however, rose to Rs 524.98 crore for the fourth quarter in 2005-06 from Rs 375.99 crore in the year-ago period, up 39.62 per cent, the company informed the Bombay Stock Exchange.

Hindustan Times - your fastest source for breaking news! Read now.

The Board of Directors of the company also recommended the issuing bonus equity shares in the ratio of 1:1, where one equity share would be issued for each share held including American depository shares.

The board has also recommended a 100 per cent final dividend of Rs 5 per share of face value of Rs 5.

For the year ended March 31 the company recorded over a three fold rise in net profit at Rs 211.12 crore as against Rs 65.46 crore for the year 2004-05. The total income (net of excise) increased to Rs 2136.57 crore for FY 05-06 from Rs 1629.04 crore in FY 04-05.

The Group posted a consolidated net profit of Rs 146.73 crore for the year 2005-06 as compared to Rs 32.91 crore for the year 2004-05.

Consolidated total income (net of excise) of the group stood at Rs 2483.21 crore for FY 05-06 as compared to Rs 1907.80 crore in FY 04-05.

Commenting on the full year results, DRL Chief Executive Officer GV Prasad said, the company was able to improved short-term profitability without compromising long-term strategic initiatives.

Revenues from international markets grew by 25 per cent to Rs 1600 crore while that from the domestic market grew by 24 per cent to Rs 800 crore.

The combined revenues from acquisitions of Betapharm and CPS business in Mexico were at Rs 150 crore, it added.

DRL said there was a decrease in R&D investments by 23 per cent to Rs 220 crore due to partnerships with US generic companies, which helped to reduce investments by Rs 38.4 crore.

Excluding this benefit, R&D investments decreased by Rs 26.6 crore compared to FY05, on account of lower R&D expenses in generics and discovery, it added.

The revenues in the API business increased by 19 per cent to Rs 820 crore in FY06 from Rs 690 crore in the previous fiscal, driven primarily by sales of terbinafine, montelukast and sertraline, it saiad.

Customs pharmaceuticals services business revenues increased to Rs 132.7 crore from Rs 31.2 crore in the previous fiscal, it said.

Unveiling Elections 2024: The Big Picture', a fresh segment in HT's talk show 'The Interview with Kumkum Chadha', where leaders across the political spectrum discuss the upcoming general elections. Watch now!

Get Current Updates on India News, Election 2024, Arvind Kejriwal News Live, Bihar Board 10th Result 2024 Live along with Latest News and Top Headlines from India and around the world.
SHARE THIS ARTICLE ON
Share this article
SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Friday, March 29, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On